1. Home
  2. Live Updates
  3. Actinium pharmaceuticals

Live Breaking News & Updates on Actinium pharmaceuticals

Stay informed with the latest breaking news from Actinium pharmaceuticals on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Actinium pharmaceuticals and stay connected to the pulse of your community

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Reaffirmed by HC Wainwright

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock Rating Reaffirmed by HC Wainwright
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Creative-financial-designs-inc , Institutional-trading-of-actinium-pharmaceuticals , Brandywine-global-investment-management , Sanders-morris-harris , Actinium-pharmaceuticals-trading , News-ratings-for-actinium-pharmaceuticals-daily , Analyst-recommendations-for-actinium-pharmaceuticals , Actinium-pharmaceuticals , Actinium-pharmaceuticals-inc , Actinium-pharmaceuticals-company-profile , Maxim-group

Analysts' Updated EPS Estimates for April 29th (ACRV, ALT, ALTR, AMC, ASUR, ATNI, ATNM, BHE, BIIB, CDP)

Analysts’ updated eps estimates for Monday, April 29th: Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at LADENBURG THALM/SH SH from a buy rating to a neutral rating. Altimmune (NASDAQ:ALT) was downgraded by analysts at Guggenheim from a buy rating to a neutral rating. Altair Engineering (NASDAQ:ALTR) had its neutral rating reaffirmed by analysts at Rosenblatt […]

Canada , United-states , Essex , Ontario , Stifel-nicolaus , Citigroup-inc , Essex-property-trust , Asure-software , Oppenheimer-holdings-inc , Actinium-pharmaceuticals , Barclays-plc , Technical-institute

ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024

Actinium Pharmaceuticals (NYSEMKT: ) just reported results for the first quarter of 2024. InvestorPlace Earnings is a project that leverages data from…

Actinium-pharmaceuticals , Place-earnings , News , Ggregator , Reaking-news , Uration , Edia ,

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Down 7.1%

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Shares Down 7.1%
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Sanders-morris-harris , Creative-financial-designs-inc , Maxim-group , Actinium-pharmaceuticals-stock , Actinium-pharmaceuticals-inc , Brandywine-global-investment-management , Institutional-investors-weigh-in-on-actinium-pharmaceuticals , News-ratings-for-actinium-pharmaceuticals-daily , Cantor-fitzgerald , Actinium-pharmaceuticals , Get-free-report

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Trading Down 7.1%

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Trading Down 7.1%
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Actinium-pharmaceuticals-price-performance , Actinium-pharmaceuticals , Cantor-fitzgerald , News-ratings-for-actinium-pharmaceuticals-daily , Actinium-pharmaceuticals-company-profile , Brandywine-global-investment-management , Actinium-pharmaceuticals-inc , Maxim-group , Creative-financial-designs-inc , Sanders-morris-harris , Get-free-report

Biotech Stocks: Big Pharma Eyes $25 Billion Radiopharmaceuticals Market

Biotech Stocks: Big Pharma Eyes $25 Billion Radiopharmaceuticals Market
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

Switzerland , Swiss , Sankalp-sethi , Bristol-myers-squibb , Sandesh-seth , Tema-etfs , Citeline-gheorghe , Gregory-renza , Matt-furlow , Dana-gheorghe , Novartis , Actinium-pharmaceuticals

Investment Opportunities In Biotech Amidst Federal Rate Uncertainties (ATNM)

Investment Opportunities In Biotech Amidst Federal Rate Uncertainties (ATNM)
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United-kingdom , Glasgow , Glasgow-city , Scotland , Bristol-meyers , Novo-nordisk , Group-fedwatch , Rhythm-pharmaceuticals , Phathom-pharmaceuticals , Exchange-commission , Astrazeneca , Federal-reserve

Real Estate Agent in Raleigh, NC, Guides Homeowners to Success

Real Estate Agent in Raleigh, NC, Guides Homeowners to Success
openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.

United-states , American , Eli-lilly , Vincerx-pharma-inc , Rhythm-pharmaceuticals , Corbus-pharmaceuticals-holdings-inc , Therapeutics-inc , Actinium-pharmaceuticals , Federal-reserve , Nasdaq , Phathom-pharmaceuticals , Bristol-meyers

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Given Average Recommendation of "Buy" by Analysts

Shares of Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM – Get Free Report) have been given a consensus recommendation of “Buy” by the five ratings firms that are currently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on […]

Actinium-pharmaceuticals-company-profile , Vanguard-group-inc , Maxim-group , Analyst-recommendations-for-actinium-pharmaceuticals , Northern-trust-corp , Actinium-pharmaceuticals , Blackrock-inc , Geode-capital-management , News-ratings-for-actinium-pharmaceuticals-daily , Actinium-pharmaceuticals-stock , Cantor-fitzgerald

Actinium Pharmaceuticals, Inc. Expected to Earn FY2024 Earnings of ($1.94) Per Share (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc. Expected to Earn FY2024 Earnings of ($1.94) Per Share (NYSEAMERICAN:ATNM)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Cantor-fitzgerald , Northern-trust-corp , Actinium-pharmaceuticals-company-profile , Actinium-pharmaceuticals , Vanguard-group-inc , Actinium-pharmaceuticals-stock-performance , Actinium-pharmaceuticals-inc , Bridgeway-capital-management , Maxim-group , News-ratings-for-actinium-pharmaceuticals-daily , Hedge-funds-weigh-in-on-actinium-pharmaceuticals